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Background: Vascular endothelial growth factor (VEGF) is taken up by parasitized red blood cells during malaria
and stimulates intra-erythrocytic growth of Plasmodium falciparum in vitro. The cause and consequence of this
uptake is not understood.
Methods: Plasmodium falciparum was cultured in vitro. Parasite growth and intracellular VEGF levels were assessed
using flow cytometry. Intracellular VEGF was visualized by fluorescence immunocytochemistry. Phosphorylated tyrosine
was measured by western blotting. In vivo assessment of intra-erythrocytic VEGF was performed in Plasmodium berghei
ANKA-infected C57BL/6 mice.
Results: VEGF accumulated intracellularly in infected red blood cells, particularly in schizonts. In vitro growth of
P. falciparum was unchanged when co-cultured with the anti-VEGF antibody bevacizumab or with an anti-VEGF
receptor-1 peptide. In contrast, the VEGF receptor-2 inhibitor, SU5416, dose-dependently inhibited growth. None
of the treatments reduced intracellular VEGF levels. Thus, the anti-parasitic effect of SU5416 seemed independent
of VEGF uptake. SU5416 reduced phosphorylated tyrosine in parasitized red blood cells. Similarly, the broad-spectrum
tyrosine kinase inhibitor genistein dose-dependently inhibited P. falciparum growth and reduced tyrosine phosphorylation.
Neither bevacizumab nor anti-VEGF receptor-1 peptide affected tyrosine kinase activity. Finally, in vivo uptake of VEGF
in P. berghei ANKA was demonstrated, analogous to the in vitro uptake in P. falciparum, making it a possible model for
the effects of VEGF signalling in vivo during malaria.
Conclusions: Inhibition of VEGFR-2 signalling reduces intra-erythrocytic growth of P. falciparum, likely due to tyrosine
kinase inhibition. Internalisation of VEGF in P. falciparum-infected red blood cells does not rely on VEGF receptors. The
function of in vivo uptake of VEGF can be studied in rodent malaria models.
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Plasmodium falciparum malaria is responsible for over
one million deaths annually, caused by complications like
severe anaemia and cerebral malaria (CM). The clinical
outcome of malaria is influenced by host genetics and
parasite characteristics [1-3].* Correspondence: nils.hoyer@gmail.com
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unless otherwise stated.Sequestration of parasitized red blood cells (PRBCs) in
cerebral blood vessels, resulting in local hypoxia and
neuronal damage, is a key event in the pathogenesis of
CM [2]. The angiogenic and neuroprotective glycoprotein
vascular endothelial growth factor (VEGF) can potentially
be induced by these mechanisms. Indeed, it has been
shown to be associated to malaria. In nonimmune travel-
lers and Kenyan children with malaria, VEGF is increased
in both brain tissue and blood [4,5]. Its release has
mainly been linked to hypoxia [6] since its expression is
stimulated via stabilization of hypoxia inducible factor
(HIF)-1α [7]. Also inflammation results in increased VEGFl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to severe disease [9]. In human CM, histopathological
analyses post mortem as well as studies on cerebral blood
flow in comatose patients strongly support localized
cerebral hypoxia, hypoperfusion, or both [9,10]. HIF-1α,
which has a short half-life, was undetectable in human
brain tissue post mortem, but a HIF-1α associated protein,
DEC-1 was upregulated in neurons [9]. Thus, sequestra-
tion of PRBCs followed by local cerebral hypoxia and
accumulation of HIF-1α is a possible cause of VEGF
production during CM.
There is an unexplained uptake of VEGF in a large
fraction of PRBCs during both uncomplicated and severe
malaria [9]. In fatal CM cases, the proportion of VEGF-
positive PRBCs is proportional to the degree of parasite
sequestration in cerebral blood vessels [9]. Addition of
VEGF to in vitro cultured P. falciparum increases para-
sitaemia, implying that VEGF may be a trophic factor
for the parasites [11]. VEGF uptake has been proposed
to depend on VEGF-receptor-2 (VEGFR-2), since this
receptor has been demonstrated on the red blood cell
surface in serum-enriched cultures of P. falciparum [11].
Cultivation in serum-free medium reduced the trophic
effect of VEGF concomitantly with a reduction of VEGFR-
2 on red blood cells [11]. VEGFR-2, a tyrosine kinase, is
the major mediator of the antiapoptotic, mitogenic, angio-
genic, and permeability-enhancing effects of VEGF on
endothelial cells in adult persons and the expression of
VEGFR-2 is increased during hypoxia [7].
This study was performed to investigate, whether dir-
ect inhibition of VEGF by the monoclonal anti-VEGF
antibody bevacizumab or inhibition of VEGF receptors
would reduce P. falciparum growth and prevent uptake
of VEGF into PRBCs. Furthermore the in vivo uptake of
VEGF was tested in the rodent malaria strain Plasmodium
berghei ANKA, which serves as a mouse model of CM.
Methods
In vitro culture of Plasmodium falciparum
Plasmodium falciparum strain 3D7 was cultured in human
serum-enriched medium according to standard methods
[12]. Briefly, the parasites were grown in culture flasks
at 37°C at 4% haematocrit in HEPES-buffered RPMI
1640 medium (Gibco, Life Technologies, Paisley, UK)
supplemented with 10% human serum (blood group O),
0.05 mg/ml gentamycin (Gibco), 0.18 mg/ml L-glutamine
(Sigma-Aldrich) in an atmosphere of 5% O2, 5% CO2, and
90% N2. Throughout the study, parasites were subcultured
by adding fresh group O red blood cells whenever parasit-
aemia reached 5%. Human blood was drawn from healthy
volunteers after obtaining verbal informed consent. Under
Danish regulations, this did not require approval from
an ethics committee. To produce serum, blood was
allowed to clot. After centrifugation serum was aspirated,immediately frozen, and stored at −20°C until used. All
experiments were performed in triplicate and repeated at
least three times, unless stated otherwise.
Inhibition of VEGF, VEGFR-1 and VEGFR-2
At day 0, 50 μL of a healthy malaria culture with a
haematocrit of 50% and a parasitaemia of 0.4% was
added to 150 μL of culture medium in microtitre plates.
Prior to seeding, PRBCs were enriched for ring stages by
centrifugation on 5% sorbitol (Sigma-Adrich) as previously
described [13]. Culture medium was carefully sampled and
replaced by pre-warmed medium.
For direct VEGF inhibition, the humanized monoclo-
nal anti-VEGF antibody bevacizumab (Avastin, Roche,
Denmark) was added daily to the growth medium, result-
ing in the following concentrations in four different
groups: 10 nM, 100 nM, 1,000 nM, and 10 μM. To allow
for binding between bevacizumab and any VEGF in the
growth medium, bevacizumab and growth medium were
mixed at least one hour prior to addition to the culture.
Growth medium with phosphate buffered saline (PBS)
added instead of bevacizumab was used as control.
For VEGFR-1 inhibition, the anti-VEGFR-1 peptide
which blocks the VEGF binding site on VEGFR-1 [14]
(Anaspec, CA, USA) was added daily to the growth
medium resulting in concentrations of 7 μM, 22 μM,
67 μM, and 200 μM respectively, at least one hour prior
to addition to the culture. Growth medium with PBS
added instead of anti-VEGFR-1 was used as control.
For VEGFR-2 inhibition, the VEGFR-2 inhibitor SU5416
(Tocris Bioscience, UK) was added daily to the growth
medium, resulting in concentrations of 4 μM, 20 μM,
100 μM, and 500 μM respectively, at least one hour prior
to addition to the culture. Growth medium with dimethyl
sulphoxide (DMSO, Sigma-Aldrich, Denmark) added
instead of SU5416 was used as control.
Inhibition of tyrosine kinase activity
For inhibition of tyrosine kinase activity a broad-acting
inhibitor, genistein (Sigma-Aldrich, Denmark) was used.
Genistein was used at four concentrations: 1, 4, 16, and
64 μg/ml, which were prepared at least one hour prior
to addition to the culture. Growth medium with DMSO
added instead of genistein was used as control. These
concentrations were also applied for growth inhibition
assays.
Immunocytochemistry
Thin blood smears of cultured blood were fixed in a
mixture of 25% acetone (Merck Chemicals, Germany) and
75% absolute ethanol (Bie & Berntsen A/S, Denmark).
After fixation, slides were permeabilized with 0.1% triton
x-100 (Sigma-Aldrich, Denmark) and blocked with 5%
bovine serum albumin (Sigma-Aldrich, Denmark) for one
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(rabbit anti-VEGF Ab-1, ThermoScientific, Denmark) at a
concentration of 0.01 mg/mL, and secondary antibody
(goat anti-rabbit Alexa Fluor 488, Life Technologies,
Denmark) at a concentration of 0.5 μg/mL, were followed
by a nuclear stain (DAPI, Life Technologies). Samples
without primary antibody served as negative controls. The
negative control was further verified by pre-incubation
where an excess (1.5x) of mouse VEGF (R&D Systems,
UK) was added to the primary antibody 0.5 hours prior to
incubating on the thin blood smears. Slides were covered
with anti fade reagent (Slow Fade Gold anti fade reagent,
Life Technologies) and cover slipped.
Fluorescence microscopy
Light immunofluorescence microscopy photos were taken
with an Olympus BX40 microscope equipped with an
Olympus DP71 digital camera. DAPI (Olympus filter cube
WU, excitation 330–385, emission 420) and fluorescein
(3540B, excitation 482/35, emission 536/40, Olympus)
filters were used. VIS (version 2.14.10.0) was used to
acquire and save images. ImageJ (version 1.44i [15]) was
used for further processing. Parasite development stage
was determined by the number of parasite nuclei per red
blood cell. Red blood cells with three or more distinguish-
able parasite nuclei were considered late stage.
Confocal microscopy
Confocal immunofluorescence microscopy photos were
taken with a Nikon TE 2000E Eclipse, with 360 numerical
aperture, 1.4 Apoplan oil immersion objective lens, with
gain adjusted for each laser (515/30, 605/75). Z-stacks
were generated with Nikon EZ-C1 software with z-steps
of 0.15 μm.
Flow cytometry
Parasitaemia was determined daily by staining of samples
with acridine orange (Sigma-Aldrich, Denmark) followed
by flow cytometry as previously described [16]. Samples
were processed on a FACSCanto flow cytometer (BD
Biosciences, USA). Ten thousand events were recorded
for each sample and the resulting scatter plots were
analysed using the Weasel software (The Walter and
Eliza Hall Institute of Medical Research, version 3.0).
For the detection of intracellular VEGF in PRBCs by
flow cytometry at day 3, when late-stage parasites were
predominant, cells were fixed in 1% paraformaldehyde
(Ampliqon, Denmark) for 10 min at room temperature.
After washing in PBS, the cells were permeabilized in
0.1% saponin (Sigma-Aldrich, Denmark) for 10 min.
Intracellular VEGF was detected by incubating 5×105 cells
for 40 min with mouse anti-human VEGF conjugated to
allophycocyanin (2 μg/ml, clone 23410, R&D Systems)
according to manufacturer’s instructions. The reactivitywas compared with a relevant isotype control (2 μg/ml,
R&D Systems). Fifty thousand events were recorded
using the 633 HeNe laser. The DNA binding dye Syto-9
(5 μM, Life Technologies) was added to the staining
solution. This made it possible to discriminate PRBCs,
which contain DNA, from nonparasitized red blood
cells, which do not contain DNA. The precision of this
detection of PRBCs was comparable with acridine orange
(p > 0.61). The 488 nm Argon laser was used for Syto-9.
Data analyses were carried out using FlowJo version 7.6.5
(Three Star Inc, OR, USA).Western blotting
At day 1, late-stage PRBCs were lysed in PhosphoSafe
(Merck Chemicals, Germany) to preserve the current
phosphorylation of proteins according to the manufac-
turer’s instructions. The lysates were stored at −20°C
until western blotting was performed. Protein content
was determined using the Lowry assay (DC protein assay,
Bio-Rad, CA, USA). The proteins were separated on 10%
polyacrylamide gels (BisTris mini, Life Technologies) at
150 V using MES buffer (Life Technologies). Twenty μg
protein was loaded into each well and electrophoresis
was carried out under denaturing and reducing conditions.
Proteins were transferred to polyvinylidene membranes
(ImmunBlot, Bio-Rad) at 30 V for one hour. The mem-
branes were blocked with 5% bovine serum albumin
(Sigma-Aldrich, Denmark) for one hour at room tempera-
ture before being incubated with an anti-phosphorylated
tyrosine (pTyr) antibody at 4°C overnight (2000 × dilution,
Cell Signaling Technology, MA, USA). The primary anti-
body was detected using a goat anti-mouse horseradish
peroxidase-conjugated secondary antibody (Dako, Glostrup,
Denmark). Bands were detected using SuperSignal West
Femto Substrate (Pierce, Thermo Fischer, IL, USA). The
bands were quantified using open-access Fiji software
[17]. The bands were normalized to total protein content
of the well by shortly staining the membrane in 0.25%
Coomassie Blue and destaining overnight according to
standard methods before scanning the membrane in
epi-illumination mode (Chemidoc XRS, Bio-Rad). This
experiment was performed three times in duplicate.Animal experiments
Female, pathogen-free, six- to eight-week old C57/Bl6
mice (Taconic, Ejby, Denmark) were infected by intra-
peritoneal (ip) injection of P. berghei ANKA (inoculum
size = 104 PRBCs). Animals were treated according to
standard protocols and given food and water ad libitum.
The experiment was approved by the Danish Animals
Inspectorate (license number 2006/561-1128). On day 8,
peripheral blood was collected for thin blood smears
and processed for immunocytochemistry as described.
Figure 1 Immunocytochemistry (ICC) of cultured human red blood cells infected with Plasmodium falciparum and peripheral blood
smears from mice infected with Plasmodium berghei ANKA show uptake of VEGF into late stage parasites, not inhibited by blocking
VEGFR-2 or VEGF. Fluorescence microscopy of thin blood smears after culture of human blood infected with P. falciparum with no inhibition
(A), SU5416 (B), or bevacizumab (C). DNA is stained blue by DAPI, VEGF is stained green. Uninfected red blood cells and most early stage parasitized
red blood cells (containing a maximum of two DNA fragments) did not stain positive for VEGF. Inlets present 1.5 x enlargement of marked area on
the slide. Bar size = 10 μm. Thin blood smears taken from mice infected with P. berghei ANKA (D) showed similar staining compared to culture of
human blood. Inlet presents 2 x enlargement of marked area on the slide. Bar size = 10 μm. Manual counting of parasitized red blood cells showed
a significant increase in VEGF uptake in late stage PRBCs (containing more than two DNA fragments) compared to early stages (p = 0.038, E).
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Figure 2 Inhibition of VEGFR-2 but not VEGFR-1 or VEGF reduces parasitaemia in cultures of Plasmodium falciparum. Unspecific inhibition of
tyrosine kinases also reduces parasitaemia in cultures. Growth curves of cultures of human blood cells infected with P. falciparum, in the presence of
bevacizumab (A), SU5416 (B), anti-VEGFR-1 (C), or genistein (D) in increasing concentrations. Controls contain only PBS or DMSO respectively.
Inhibition of VEGF by bevacizumab (A) did not affect parasitaemia, whereas inhibition of VEGFR-2 by SU5416 (B) resulted in a significantly
reduced parasitaemia in a dose-dependent manner compared to DMSO controls. Inhibition of VEGFR-1 by anti-VEGFR-1 (C) did not replicate
this effect and had no effect on parasitaemia. Addition of the unspecific tyrosine kinase inhibitor genistein (D) resulted in a significant reduction in
parasitaemia compared to DMSO.
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Data did not meet the criteria for using parametric tests.
Kruskal-Wallis test was applied for comparing multiple
groups and Mann–Whitney U test was used post hoc.
A p-value less than 0.05 was considered statistically
significant. All statistical analyses were performed with
the R-commander software [18].
Results
VEGF uptake in PRBCs
Culture of P. falciparum in serum-enriched growth
medium resulted in uptake of VEGF into PRBCs, deter-
mined by immunocytochemistry on day 6 after the first
addition of serum (Figure 1). Neither uninfected red
blood cells nor free parasites stained positive for VEGF
(Figure 1). This was confirmed by flow cytometry. Confocal
microscopy at high magnification showed that VEGF
was located intracellularly, in relation to the parasites
(Additional file 1: Movie 1). Pre-incubation of the primary
anti-VEGF antibody with an excess of murine VEGF prior
to incubation almost completely abolished staining for
VEGF. The incidence of VEGF uptake was significantly
increased in late stages of the malaria parasite (with de-
tection of VEGF in 60.7% of PRBCs), compared to early
stages (VEGF in 6.7% of PRBCs, p = 0.038, Figure 1E).
Direct inhibition of VEGF by bevacizumab does not
reduce parasitaemia
Direct inhibition of VEGF in the growth medium was
obtained by adding the humanized monoclonal anti-
VEGF antibody bevacizumab. Flow cytometric analyses
showed that parasitaemia did not change significantly
compared to PBS-treated controls on any day until the
experiment was ended (p > 0.06, Figure 2A).
Inhibition of VEGFR-2 by SU5416 significantly reduces
parasitaemia
Inhibition of VEGFR-2 was obtained by addition of the
VEGFR-2 inhibitor SU5416 to the growth medium. This
treatment resulted in a significant and dose dependent
decrease in parasitaemia as compared to DMSO treated
controls from day 2 and onwards (p < 0.05, Figure 2B).
At day 2 all doses but 4 μM resulted in significant
growth retardation (p < 0.01). On day 3 and 4 only the two
highest doses (100 and 500 μM) significantly reducedgrowth (p < 0.01), while at 20 μM it was statistically indis-
tinguishable from DMSO (p > 0.12). Four μM SU5416
did not reduce the parasitaemia in culture compared to
control during experiments (p > 0.07, Figure 2B).
Direct inhibition of VEGFR-1 does not reduce parasitaemia
Direct inhibition of VEGFR-1 in the growth medium was
obtained by adding a peptide binding to VEGFR-1 thereby
inhibiting its interaction with VEGF. This treatment did
not significantly affect parasite growth compared to PBS-
treated controls on any day of the experiment (p > 0.06,
Figure 2C).
Treatment with bevacizumab, SU5416 or anti-VEGFR-1
does not cause reduced VEGF accumulation
The intracellular accumulation of VEGF was studied in par-
allel with the progression of parasitaemia by flow cytometry
analyses of the median fluorescence intensity after staining.
This did not reveal any reduction in VEGF accumulation
after four days of treatment with bevacizumab (p > 0.51),
SU5416 (p > 0.06), or anti-VEGFR-1 (p > 0.34) compared to
DMSO and PBS controls respectively (Figure 3A-C). The
flow cytometric results were confirmed by immunocyto-
chemistry, showing VEGF staining of PRBCs despite treat-
ment with SU5416 (Figure 1B) or bevacizumab (Figure 1C).
DNA content of PRBCs upon SU5416 and bevacizumab
stimulation
Previous studies have indicated that VEGF is trophic for
parasite growth [11]. One mechanism by which SU5416
could reduce parasite growth could be through reduction
of the number of merozoites per schizont, which has pre-
viously been shown to affect parasite growth rate [19],
thus reducing the number of newly infected red blood
cells after schizont rupture. However, analyses of flow cy-
tometric data (median fluorescence intensity of DNA
binding dye Syto-9) did not support that either SU5416
(p = 0.054) or bevacizumab (p = 0.095) reduced the DNA
content of the PRBCs.
Genistein dose-dependently decreases parasitaemia
Since no association between inhibition of parasite growth
and intracellular VEGF was found, an alternative anti-
parasitic mechanism of SU5416 was sought. SU5416
inhibits VEGFR-2 signalling as a tyrosine kinase inhibitor.
Figure 3 Intracellular VEGF content in parasitized red blood cells (PRBCs) is not affected by inhibiting VEGF, VEGFR-2, VEGFR-1, or
tyrosine kinases. Median fluorescence intensity of PRBCs collected at day 3 from cultures of P. falciparum after staining for intracellular VEGF,
determined by flow cytometry. Neither inhibition of VEGF by bevacizumab (A), nor specific inhibition of VEGFR-2 by SU5416 (B), or VEGFR-1 by
anti-VEGFR-1 peptide (C) significantly altered the accumulation of VEGF in PRBCs. Broad inhibition of tyrosine kinases by adding genistein (D) had
no effect on accumulation of VEGF in PRBCs.
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sine kinase inhibitor, on intra-erythrocytic growth of P.
falciparum was tested. As seen in Figure 2D genistein
inhibited growth significantly in a dose-dependent manner
(p < 0.02), while not preventing VEGF accumulation in
PRBCs (Figure 3D).SU5416 and genistein dose-dependently reduce
phosphorylation of tyrosine
The effect of SU5416 on tyrosine phosphorylation was
investigated and compared with the other treatments
applied. SU5416 and genistein dose-dependently reduced
tyrosine phosphorylation in PRBCs (Figure 4A-B), whereas
anti-VEGFR-1 peptide and bevacizumab did not show any
effect on this parameter (Figure 4C-D).Uptake of VEGF into red blood cells infected with
Plasmodium berghei ANKA
The murine malaria parasite P. berghei ANKA, when
infecting mice in vivo, internalized VEGF similarly to the
in vitro experiments. Peripheral blood smears, collected
after eight days of infection, showed a marked uptake of
VEGF into PRBCs, primarily in schizonts (Figure 1D).
Confocal microscopy showed that VEGF was located
intracellularly (Additional file 2: Movie 2). Analogous tothe in vitro results with P. falciparum, non-PRBCs and
free parasites did not stain for VEGF (Figure 1D).
Discussion
The presented results strengthen the evidence of VEGF
uptake during in vitro culture of P. falciparum [11] and
suggest that uptake of VEGF depends on parasite maturity.
However, the mechanism behind this uptake remains
unclear. This may not be an active process since applying
an excess level of anti-VEGF antibody neither affects
growth nor intracellular VEGF levels. A dedicated VEGF
transporter would likely be hindered by VEGF being of
different size or having potential binding sites blocked
by the antibody. It is known that the red blood cell
membrane in late-stage parasites becomes leaky [20],
which could augment internalization of VEGF. Similarly,
there is an intracellular accumulation of VEGFR-1 in
late-stage parasites (unpublished observation). Previous
reports suggest that VEGF acts as a trophic factor for
parasite growth since addition of VEGF to an in vitro
parasite culture increased parasitaemia and partly rescued
the culture from pre-treatment with artesunate [11]. As it
was not possible to reduce intracellular VEGF, this effect
could not be assessed further.
Besides being a trophic factor, a possible advantage of
VEGF accumulation could be the removal of VEGF from
Figure 4 Specific or unspecific inhibition of VEGFR-2, by addition of SU5416 or genistein to cultures of Plasmodium falciparum, reduces
phosphorylation of several tyrosine kinases in red blood cells. This result is not replicated by addition of anti-VEGFR-1 or bevacizumab. Median
intensity of bands, obtained by staining western blots of red blood cells after culture, for several phosphorylated tyrosine kinases, with molecular
weights of 30, 55, 60, 70, and 90 kDa respectively. Cultures were performed in duplicate with the addition of increasing concentrations of
SU5416, genistein, anti-VEGFR-1, or bevacizumab. SU5416 (A) and genistein (B) inhibited several of the tested tyrosine kinases in a dose
dependent manner. This was not the case for anti-VEGFR-1 (C) or bevacizumab (D).
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and epithelial VEGF production is increased during cere-
bral hypoxia, resulting in nitric oxide (NO)-dependent
vasodilation, increased angiogenesis, and thus increased
oxygen delivery to the tissue [6]. Because of the micro-
aerophilic nature of P. falciparum [21], these changes are
potentially detrimental to the parasite, making it a good
survival strategy to remove VEGF.
Avoidance of the host immune system is a third possible
rationale for VEGF uptake. VEGF is known to stimulate
monocyte and T-cell chemotaxis [22,23]. Circulating
monocytes and resident macrophages contribute to
parasite clearance by phagocytizing PRBCs, and are
present in increased numbers in cerebral vessels withsequestration [24]. Thus, removal of VEGF from the
cerebral micro-environment could reduce local host
immune responses and allow parasite sequestration in
the cerebral microvasculature.
Confocal microscopy proved that VEGF was located
intracellularly in the PRBCs. This excludes that positive
staining for VEGF in PRBCs was due to adsorption
onto the PRBC surface rather than absorption. Con-
focal microscopy did not allow to determine the precise
intracellular distribution of VEGF. However it did show
that at least some VEGF is present in the parasitophorous
vacuoles.
Both microscopy and flow cytometry showed that
VEGF uptake was not significantly reduced despite
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neither by VEGFR-1 nor VEGFR-2 inhibition. However,
inhibition of VEGFR-2 signalling significantly decreased
parasitaemia in this study. The antiparasitic action of
VEGFR-2 inhibition despite unchanged VEGF accumu-
lation suggests that this effect is not directly related to
uptake of VEGF. Instead, SU5416 possibly inhibits the
intracellular downstream signalling cascade relating to
VEGFR-2 activation. VEGFR-2 is a receptor tyrosine
kinase. It exerts its effects, e.g. angiogenesis and tumour
growth, via intracellular phosphorylation of tyrosine
[25,26]. Indeed, P. falciparum also relies on tyrosine
kinase activity [27]. Co-culturing P. falciparum with
genistein, a broad-acting tyrosine kinase inhibitor, dose-
dependently reduced parasite growth, as previously shown
[28,29]. Western blotting of phosphotyrosine levels in
late-stage parasites supported the concept that SU5416
directly inhibited parasite tyrosine kinases, as several loci
had reduced phosphotyrosine levels. Comparable results
were obtained with genistein though it seemed to inhibit a
broader range of kinases. Additional research is needed to
further assess the association between tyrosine kinase
inhibition and the anti-parasitic effect of SU5416 and
genistein.
Many studies on the pathogenesis of CM are performed
in a mouse model, infected with the rodent Plasmodium
strain P. berghei ANKA, because of its accessibility as well
as clinical and histopathological similarities to human CM
[30]. The presented results show in vivo uptake of VEGF
into murine PRBCs infected with P. berghei ANKA, simi-
lar to human PRBCs. VEGF was located intracellularly in
late-stage PRBCs. Thus future studies of VEGF inhibitors
may be performed in vivo using this experimental model.
In summary, inhibition of VEGFR-2 signalling reduces
intra-erythrocytic growth of P. falciparum, but this
reduction does not correlate with intracellular levels of
VEGF. Rather, it may depend on inhibition of parasite
tyrosine kinase activity. The effect of VEGF on parasite
growth remains to be clarified. Since VEGF also accu-
mulates in late-stage P. berghei ANKA PRBCs in vivo,
the relevance of VEGF signalling may be addressed in
experimental infections.Additional files
Additional file 1: Movie 1. Z-stack obtained by confocal microscopy
showing intracellular VEGF in cultured human red blood cells infected
with Plasmodium falciparum. DNA is stained blue and VEGF is stained
green by immunocytochemistry. The stack shows VEGF located intracellularly.
The z-stack was generated with Nikon EZ-C1 software with z-steps of
0.15 μm.
Additional file 2: Movie 2. Z-stack obtained by confocal microscopy
showing intracellular VEGF in murine red blood cells infected with
Plasmodium berghei ANKA during experimental CM. DNA is stained blue
and VEGF is stained green by immunocytochemistry. The stack confirmsthat VEGF is located intracellularly and shows a similar pattern of distribution
as cultured human red blood cells infected with P. falciparum. The z-stack was
generated with Nikon EZ-C1 software with z-steps of 0.15 μm.
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